As of 2025-07-10, the Intrinsic Value of Oasmia Pharmaceutical AB (OASM.ST) is (3,557.60) Oasmia Pharmaceutical. This OASM.ST valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1.69 Oasmia Pharmaceutical, the upside of Oasmia Pharmaceutical AB is -121,935.50%.
The range of the Intrinsic Value is (40,496.72) - (1,834.11) Oasmia Pharmaceutical
Based on its market price of 1.69 Oasmia Pharmaceutical and our intrinsic valuation, Oasmia Pharmaceutical AB (OASM.ST) is overvalued by 121,935.50%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (40,496.72) - (1,834.11) | (3,557.60) | -121935.5% |
| DCF (Growth 10y) | (24,002,584.33) - (637,781,840.05) | (51,025,715.37) | -1747456105.8% |
| DCF (EBITDA 5y) | (1,566.30) - (2,678.79) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (20,777,545.29) - (42,828,974.54) | (1,234.50) | -123450.0% |
| P/E | (7.77) - (14.26) | (7.27) | -348.8% |
| EV/EBITDA | (4.48) - (6.81) | (5.72) | -295.9% |
| EPV | 16.07 - 28.36 | 22.22 | 660.9% |
| DDM - Stable | (4.36) - (208.93) | (106.65) | -3752.2% |
| DDM - Multi | (1,222.51) - (47,754.53) | (2,439.90) | -83658.4% |
| Market Cap (mil) | 907.95 |
| Beta | 0.47 |
| Outstanding shares (mil) | 538.04 |
| Enterprise Value (mil) | 1,383.31 |
| Market risk premium | 5.22% |
| Cost of Equity | 7.34% |
| Cost of Debt | 7.00% |
| WACC | 7.30% |